多发性骨髓瘤 中国就医指南

Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the uncontrolled proliferation of clonal plasma cells within the bone marrow. These abnormal cells produce monoclonal immunoglobulins (M-proteins) or free light chains, leading to end-organ damage—commonly summarized by the CRAB criteria: hyperCalcemia, Renal insufficiency, Anemia, and Bone lesions (e.g., lytic lesions, osteoporosis, pathologic fractures). Pathogenesis involves progressive genetic alterations—including translocations involving the immunoglobulin heavy chain locus (e.g., t(11;14), t(4;14)), deletions (e.g., del(17p)), and mutations in genes such as KRAS, NRAS, BRAF, and TP53—that drive dysregulated cell survival, proliferation, and evasion of apoptosis. The bone marrow microenvironment plays a critical role, with cytokines like IL-6, BAFF, and APRIL promoting myeloma cell growth and drug resistance. Epidemiologically, MM accounts for approximately 10% of all hematologic malignancies and 1–2% of all cancers globally. Incidence rises sharply with age, with a median diagnosis age of 69 years; it is rare under age 40. In China, age-standardized incidence is estimated at 1.0–1.3 per 100,000 person-years, with slightly higher rates in males than females. Known risk factors include monoclonal gammopathy of undetermined significance (MGUS)—a precursor condition present in >90% of MM cases—as well as advancing age, male sex, African ancestry (2–3× higher incidence vs. Asian or Caucasian populations), obesity, and occupational exposure to radiation or certain chemicals (e.g., benzene, pesticides). Family history also confers modest increased risk. Quality of life (QoL) is profoundly impacted: chronic bone pain, fatigue from anemia, recurrent infections due to immunoparesis, renal dysfunction requiring dialysis, and treatment-related toxicities (e.g., peripheral neuropathy, cytopenias, cognitive changes) contribute to physical disability, emotional distress, social withdrawal, and reduced functional independence. Patients often experience anxiety about disease progression and treatment burden, especially during prolonged maintenance therapy. Early diagnosis remains challenging due to nonspecific symptoms—such as fatigue, back pain, or recurrent sinusitis—which may delay referral to hematology. With modern therapies—including proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory drugs (lenalidomide, pomalidomide), monoclonal antibodies (daratumumab, isatuximab), and emerging BCMA-targeted agents (bispecific antibodies, CAR-T cells)—median overall survival has improved to 7–10 years in fit patients, though outcomes vary significantly by cytogenetic risk, access to novel agents, and supportive care infrastructure.

# 多发性骨髓瘤治疗方案与费用明细（血液科）

一、非手术/药物治疗方案

适用人群：初诊、老年、体能状态差（ECOG ≥2）、肾功能不全或不适合移植者。

• •一线方案（RVD/VRd）：来那度胺+硼替佐米+地塞米松，年药费 8–15万元（国产仿制药至原研药梯度）；含每月血常规、肝肾功、游离轻链检测（300–500元/次），骨髓穿刺+流式细胞学（2800–4200元/次）。
• •维持治疗（来那度胺单药）：年费用 4–9万元；每3月复查M蛋白、影像学（全身低剂量CT或PET-CT，6000–12000元/次）。

二、核心介入/根治性方案

适用人群：年龄≤65岁、ECOG≤2、无严重心肾合并症、适合自体造血干细胞移植（ASCT）。

• •ASCT全流程：动员（G-CSF+普乐沙福）、采集、冻存、清髓预处理（马法兰）、回输及支持治疗；总费用 22–35万元（含术前检查：心脏超声+肺功能+感染四项+HLA配型等，4500–7200元）。

三、特殊复杂情况方案

• •复发/难治性（RRMM）：BCMA靶向疗法（如西达基奥仑赛CAR-T），单疗程 129.8万元（医保谈判后自付约35–50万元）；双抗（泰金博单抗）年治疗费 60–85万元。
• •骨病并发症：椎体成形术（单节段）2.8–4.5万元；放疗（局部姑息）1.2–2.6万元/疗程。

方案快速选择指南

✅ 预算有限/老年患者：优选国产RVD方案+维持治疗（首年总支出约12–20万元） ✅ 年轻可耐受者：ASCT为标准根治路径（首年投入25–40万元，长期PFS显著延长） ✅ 三线以上复发：优先评估CAR-T或双抗临床试验（部分项目减免药费）